Overview
Chronic hepatocerebral degeneration is an autosomal recessive mitochondrial disorder characterized by severe mitochondrial DNA depletion, primarily affecting the liver and brain, leading to liver failure, neurological symptoms, and developmental delays. It can be associated with mutations in genes such as MPV17, TWINKLE, POLG1, and DGUOK 1.Diagnosis
Clinical Presentation: Infantile onset with liver failure, hypoglycemia, failure-to-thrive, and neurological symptoms including developmental delay and encephalopathy 1.
Genetic Testing: Identification of mutations in MPV17 gene, including novel mutations like p.K88E, p.G94R, p.P98L, p.A162D, p.L91del, splice site substitutions, and insertions 1.
Mitochondrial DNA Analysis: Assessment of mitochondrial DNA content and integrity to confirm depletion 1.Management
Supportive Care: Management of liver failure with appropriate nutritional support, hydration, and symptomatic treatment for neurological symptoms 1.
Liver Transplantation: Consideration for liver transplantation in cases of end-stage liver disease, though neurological outcomes may vary 1.
Genetic Counseling: Essential for families to understand recurrence risks and implications for future pregnancies 1.Special Populations
Pediatrics: Early recognition and intervention are critical due to the infantile onset and rapid progression of symptoms 1.
Comorbidities: Management must address concurrent issues like hypoglycemia and malnutrition alongside primary disease manifestations 1.Key Recommendations
Genetic Testing for MPV17 Mutations: Routine genetic testing for MPV17 mutations in patients presenting with hepatocerebral symptoms, especially in cases of infantile liver failure and neurological deficits (Evidence: Moderate) 1.
Consider Liver Transplantation: Evaluate liver transplantation as a therapeutic option for patients with end-stage liver disease secondary to MPV17-associated hepatocerebral degeneration (Evidence: Expert opinion) 1.
Comprehensive Supportive Care: Implement multidisciplinary supportive care addressing both hepatic and neurological manifestations to improve quality of life (Evidence: Moderate) 1.References
1 El-Hattab AW, Li FY, Schmitt E, Zhang S, Craigen WJ, Wong LJ. MPV17-associated hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel mutations. Molecular genetics and metabolism 2010. link